Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 16/18: Neoadjuvant Radio-immunotherapy in Resectable Stage III(N2) NSCLC
NCT04245514Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Event-Free Survival at 12 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04245514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245514.